Carbinoxamine in some unapproved cough medicines has been recalled by theFDA. There are possible health risks to children. A FDA recall has been issued.
Carbinoxamine containing cough medicines and many other types on the market have been unapproved by the Food and Drug Administration. Some can pose serious health risks, particularly to young children. Because of this, the agency on launched a campaign to stop these unapproved drug makers.
Products with carbinoxamine need FDA approval to be marketed, but numerous products such products, either alone or in combination with other active ingredients, are marketed without FDA approval, the agency states.The FDA will begin its efforts by watching the use of the antihistamine carbinoxamine, which the agency states can be hurtful to younger children under the age of two. The federal agency has given cough drop manufacturers using carbinoxamine 30 to 90 days to stop their sale of the unapproved drug.
NOTE: Presently, only one branded drug, Palgic, is FDA approved as a single-entity antihistamine in the United States.
If you or a loved one has suffered serious injury or death as a result of an unapproved cough medicine with carbinoxamine maleate, then contact our law firm for a free case evaluation. No fees or expenses charged, unless we make a recovery for you.